Janus Kinases

• 

  Subject Areas on Research

  • A comparative transcriptomic analysis of astrocytes differentiation from human neural progenitor cells. 
  • Accelerated cell cycles enable organ regeneration under developmental time constraints in the Drosophila hindgut. 
  • Akt is required for Stat5 activation and mammary differentiation. 
  • Beta-arrestins and cell signaling. 
  • Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. 
  • Constitutive Interferon Maintains GBP Expression Required for Release of Bacterial Components Upstream of Pyroptosis and Anti-DNA Responses. 
  • Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. 
  • Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. 
  • Enterovirus 2Apro Cleavage of the YTHDF m6A Readers Implicates YTHDF3 as a Mediator of Type I Interferon-Driven JAK/STAT Signaling. 
  • Exercise mimetics and JAK inhibition attenuate IFN-γ-induced wasting in engineered human skeletal muscle. 
  • Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia. 
  • High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease. 
  • Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. 
  • Inositol phosphate kinase 2 is required for imaginal disc development in Drosophila. 
  • Interorgan regulation of Drosophila intestinal stem cell proliferation by a hybrid organ boundary zone. 
  • JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. 
  • JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. 
  • JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats. 
  • Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. 
  • Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. 
  • Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma. 
  • Requirement for JAK/STAT signaling throughout border cell migration in Drosophila. 
  • SOCS36E, a novel Drosophila SOCS protein, suppresses JAK/STAT and EGF-R signalling in the imaginal wing disc.